Impaired energetics in heart failure - a new therapeutic target.
Heart failure is a syndrome of huge and growing importance worldwide. It is widely accepted that the energy status of the myocardium in heart failure is impaired, irrespective of etiology. Agents which modify cardiac substrate utilisation have the potential to ameliorate this energy deficiency by increasing cardiac mechanical efficiency. This may represent a new therapeutic paradigm in heart failure. In this review we discuss existing and new agents that alter cardiac substrate use and summarise the data on clinical efficacy.
Ormerod
Julian O M
JO
Department of Cardiovascular Medicine, University of Birmingham, United Kingdom.
Ashrafian
Houman
H
Frenneaux
Michael P
MP
D000818:Animals; D050260:Carbohydrate Metabolism / Q000187:drug effects; D004734:Energy Metabolism / Q000187:drug effects*; D006333:Heart Failure / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D006801:Humans; D008954:Models, Biological; D009206:Myocardium / Q000378:metabolism* / Q000473:pathology; D010084:Oxidation-Reduction / Q000187:drug effects